Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
Authors
Keywords
-
Journal
LANCET ONCOLOGY
Volume 23, Issue 1, Pages 53-64
Publisher
Elsevier BV
Online
2021-11-25
DOI
10.1016/s1470-2045(21)00578-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma
- (2021) Mary Jane Lim-Fat et al. JOURNAL OF NEURO-ONCOLOGY
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
- (2021) David N Louis et al. NEURO-ONCOLOGY
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
- (2020) Patrick Y Wen et al. NEURO-ONCOLOGY
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- (2020) Vivek Subbiah et al. LANCET ONCOLOGY
- BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
- (2019) Karisa C. Schreck et al. Cancers
- Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study
- (2019) Darren R. Hargrave et al. CLINICAL CANCER RESEARCH
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
- (2018) Rimas V. Lukas et al. JOURNAL OF NEURO-ONCOLOGY
- On high-risk, low-grade glioma: What distinguishes high from low?
- (2018) Marjolein Geurts et al. CANCER
- BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study
- (2018) Thomas Kaley et al. JOURNAL OF CLINICAL ONCOLOGY
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- Diffuse Infiltrating Oligodendroglioma and Astrocytoma
- (2017) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Adult IDH wild-type lower-grade gliomas should be further stratified
- (2017) Abudumijit Aibaidula et al. NEURO-ONCOLOGY
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549–BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification
- (2015) Midea Gierke et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Survival and low-grade glioma: the emergence of genetic information
- (2015) Elizabeth B. Claus et al. Neurosurgical Focus
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capturing the Molecular and Biological Diversity of High-Grade Astrocytoma in Genetically Engineered Mouse Models
- (2015) Lionel M.L. Chow et al. Oncotarget
- The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition
- (2014) Matthew M. K. Chan et al. CANCER
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- IDH1 and IDH2 Mutations in Gliomas
- (2013) Adam L. Cohen et al. Current Neurology and Neuroscience Reports
- Clinical and prognostic features of adult patients with gangliogliomas
- (2013) S. Yust-Katz et al. NEURO-ONCOLOGY
- Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
- (2012) David A. Reardon et al. CANCER
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
- (2011) MJ van den Bent et al. LANCET ONCOLOGY
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
- (2010) James R. Perry et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now